Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine (Adelphi DSP)

Pfizer

Status

Completed

Conditions

Migraine Disorders

Study type

Observational

Funder types

Industry

Identifiers

NCT06412965

C4951066

Details and patient eligibility

About

This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.

Full description

This is a retrospective database study that aims to explore the reliability of effect with acute use of Rimegepant or triptans, to evaluate the satisfaction with Rimegepant or triptans, to evaluate willingness to continue using Rimegepant or triptans, and to explore proportion optimized on treatment with Rimegepant or triptans. The data will be extracted from the Adelphi Real World (ARW) Migraine Disease Specific ProgrammeTM (DSP) 2022 database, which was conducted across a number of countries including United States, between May 2022 and November 2022. The DSP was an observational study of clinical practice. Treatment practice data were collected by physicians (physician survey) who were asked to provide information for the next 10 patients consulting for migraine. These patients were then invited to fill out a self-completion form (patient survey) providing their own assessment on the disease and treatments.

Enrollment

528 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Patients who have episodic and/or chronic migraine
Patients age > 18
Currently prescribed rimegepant OR triptans for the acute treatment of migraine

Exclusion criteria

currently prescribed rimegepant for prevention of migraine or for both the acute treatment & prevention of migraine
Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant
Triptan Group: currently prescribed an acute treatment for migraine other than triptans